01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#HVO hVIVO PLC – Annual Report, Notice of AGM & Directorate Change May 12, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, confirms that the Company’s Annual Report and Accounts for the year ended 31 December 2024 and the Notice of Annual General Meeting (“AGM”) will be posted to shareholders today.   The 2024 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy are available to download from the Company’s website www.hvivo.com.   The Annual…

Continue reading

#HVO hVIVO PLC – COVID-19 study published in Nature Communications December 12, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that an additional peer-reviewed paper from the world’s first COVID-19 characterisation trial has been published in Nature Communications.   “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”, by Rosenheim, J. et al. is available in Nature Communications,…

Continue reading

#HVO hVIVO PLC – Notice of Results March 27, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its full year results for the twelve months ended 31 December 2023 on Tuesday 9 April 2024.   Analyst briefing   A briefing open to equity research analysts will take place on Tuesday 9 April 2024 at 12.00 pm BST. To…

Continue reading